Tag: shares

KPN has repurchased 1,655,000 KPN ordinary shares in the period from 30 June to 4 July 2025. The shares were repurchased at an average price of € 4.11 per share for a total consideration of € 6.8m. These repurchases are part of the € 250m share buyback started on 25 February 2025 and reflect KPN's commitment to structurally return additional capital to its shareholders.

Hong Kong, July 07, 2025 (GLOBE NEWSWIRE) -- Top Win International Limited (Nasdaq: SORA), through its subsidiary, AsiaStrategy Topwin SG Pte. Ltd. (“AsiaStrategy”), has announced an intention to make a tender offer (the “Announcement”) with certain other offerors for the securities of DV8 Public Company Limited (SET: DV8), a company public listed on The Stock Exchange of Thailand (“DV8”).

Urges stockholders to vote “FOR” Mr. Vazquez and Carlos Minetti on the GREEN proxy card

Reference is made to the announcement by Kaldalón hf. (“Kaldalón” or the “Company”) dated 7 July 2025 regarding the volume of share buybacks conducted in Week 27 under the Company’s share buyback program, which was announced on 30 June 2025. Due to an error in the information provided by the program's administrator, a corrected volume of buybacks for Week 27 is hereby disclosed.

PRESS RELEASE

LONDON, July 07, 2025 (GLOBE NEWSWIRE) -- MURANO GLOBAL INVESTMENTS PLC (NASDAQ: MRNO) (“Murano” or the “Company”) today announced an enhancement to its corporate strategy aimed at building a Bitcoin (BTC) Treasury. The Company will continue with its core strategy of developing real estate and operating its Mexican hotel and resort business while simultaneously leveraging its operating cash flows, substantial real estate holdings, and access to capital markets to build a robust Bitcoin Treasury.

-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population --

-- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo --